Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
Public ClinicalTrials.gov record NCT01201837. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A Phase II, Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects With Acute Coronary Syndrome
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Cardiovascular disease remains the most pressing healthcare issue for developed countries and is becoming so for developing countries. There are a number of chronic therapies available for long-term management of risk. Short term therapies for subjects with an acute event, such as an episode of acute coronary syndrome (ACS), are focused on reperfusion and removing thrombus but most subsequent events are caused by atherosclerotic plaque rupture at a different site. There are no approved therapies that can rapidly reduce the burden of unstable, inflamed plaque in the overall coronary vascular bed. HDL has multiple actions that could lead to atherosclerotic plaque stabilization, such as rapid removal of large quantities of cholesterol from the vasculature, improvement in endothelial function, protection against oxidative damage and reduction in inflammation. This study will assess the effects of CER-001, an ApoA-I-based HDL mimetic, on indices of atherosclerotic plaque progression and regression as assessed by intravascular ultrasound (IVUS) measurements in patients with (ACS).
Study identification
- NCT ID
- NCT01201837
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 507 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Up to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2011 (Type not available)
- Primary completion
- Oct 2012 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Mar 3, 2014
2011 – 2013
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Heart Center Research LLC | Huntsville | Alabama | 35801 | — |
| Mayo Clinic - Arizona | Phoenix | Arizona | 85054 | — |
| VA San Diego Health Care Center | San Diego | California | 92161 | — |
| Palm Beach Heart Institute, LLC - Zasa Clinical Research | Boynton Beach | Florida | 33472 | — |
| Heart and Vascular Institute of Florida | Clearwater | Florida | 33755 | — |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | — |
| Saint Joseph Research Institute | Atlanta | Georgia | 30342 | — |
| The Care Group, LLC | Indianapolis | Indiana | 46260 | — |
| Suburban Hospital | Bethesda | Maryland | 20814 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | — |
| Detroit Medical Center (DMC) Cardiovascular Institute | Detroit | Michigan | 48201 | — |
| Cardiac and Vascular Research Center of Northern Michigan | Petoskey | Michigan | 49770 | — |
| Alegent Research Center | Omaha | Nebraska | 68124 | — |
| Buffalo Heart Group | Buffalo | New York | 14215 | — |
| Buffalo Cardiology & Pulmonary Associates | Williamsville | New York | 14221 | — |
| University of North Carolina Medical Center | Chapel Hill | North Carolina | 27599 | — |
| LeBauer Cardiovascular Research Foundation | Greensboro | North Carolina | 27401 | — |
| Sanford Heart Center | Fargo | North Dakota | 58122 | — |
| South Oklahoma Heart Research | Oklahoma City | Oklahoma | 73135 | — |
| Penn Presbyterian Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Research / USD | Sioux Falls | South Dakota | 57104 | — |
| Baptist Memorial Hospital | Memphis | Tennessee | 38120 | — |
| Dallas VA Medical Center | Dallas | Texas | 75016 | — |
| MultiCare Health System Research Institute / Cardiac Study Center | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01201837, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01201837 live on ClinicalTrials.gov.